Who are ApatinibMesylateTablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): REGORAFENIB, Sutent, Apatinib+Capecitabine, Ramucirumab+ paclitaxel, Rivoceranib (Apatinib), Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apatinibmesylatetablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ApatinibMesylateTablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ApatinibMesylateTablets (ApatinibMesylateTablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 2 Tyrosine kinase inhibitor VEGFR2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ApatinibMesylateTablets (ApatinibMesylateTablets) — Chang-Ming Huang, Prof.. Tyrosine kinase inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ApatinibMesylateTablets TARGET	ApatinibMesylateTablets	Chang-Ming Huang, Prof.	phase 2	Tyrosine kinase inhibitor	VEGFR2
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Apatinib+Capecitabine	Apatinib+Capecitabine	Huazhong University of Science and Technology	phase 3	Tyrosine kinase inhibitor + Fluoropyrimidine antimetabolite	VEGFR2 (apatinib); Thymidylate synthase (capecitabine)
Ramucirumab+ paclitaxel	Ramucirumab+ paclitaxel	AstraZeneca	phase 3	Angiogenesis inhibitor, Microtubule inhibitor	VEGFR2
Rivoceranib (Apatinib)	Rivoceranib (Apatinib)	Jiangsu HengRui Medicine Co., Ltd.	phase 3	tyrosine kinase inhibitor	VEGFR2
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan	Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Monoclonal antibody (ramucirumab) + chemotherapy combination	VEGF receptor 2 (VEGFR2); tubulin (taxanes) / topoisomerase I (irinotecan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ApatinibMesylateTablets — Competitive Intelligence Brief. https://druglandscape.com/ci/apatinibmesylatetablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing